CRISPR Therapeutics AG (CRSP)
55.43
-0.01
(-0.02%)
USD |
NASDAQ |
Oct 02, 16:00
55.33
-0.10
(-0.18%)
After-Hours: 20:00
CRISPR Therapeutics Net Income (Quarterly) : -91.15M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -91.15M |
| March 31, 2026 | -122.93M |
| December 31, 2025 | -130.61M |
| September 30, 2025 | -106.44M |
| June 30, 2025 | -208.55M |
| March 31, 2025 | -136.00M |
| December 31, 2024 | -37.31M |
| September 30, 2024 | -85.94M |
| June 30, 2024 | -126.41M |
| March 31, 2024 | -116.59M |
| December 31, 2023 | 89.35M |
| September 30, 2023 | -112.15M |
| June 30, 2023 | -77.74M |
| March 31, 2023 | -53.06M |
| December 31, 2022 | -110.58M |
| September 30, 2022 | -174.55M |
| June 30, 2022 | -185.83M |
| March 31, 2022 | -179.22M |
| December 31, 2021 | -141.25M |
| September 30, 2021 | -127.15M |
| June 30, 2021 | 759.22M |
| March 31, 2021 | -113.16M |
| Date | Value |
|---|---|
| December 31, 2020 | -107.04M |
| September 30, 2020 | -92.44M |
| June 30, 2020 | -79.66M |
| March 31, 2020 | -69.73M |
| December 31, 2019 | 30.54M |
| September 30, 2019 | 138.42M |
| June 30, 2019 | -53.70M |
| March 31, 2019 | -48.41M |
| December 31, 2018 | -47.59M |
| September 30, 2018 | -50.71M |
| June 30, 2018 | -38.38M |
| March 31, 2018 | -28.30M |
| December 31, 2017 | 0.14M |
| September 30, 2017 | -24.71M |
| June 30, 2017 | -22.32M |
| March 31, 2017 | -21.48M |
| December 31, 2016 | 17.10M |
| September 30, 2016 | -14.69M |
| June 30, 2016 | -17.16M |
| March 31, 2016 | -8.442M |
| June 30, 2015 | -3.666M |
| March 31, 2015 | -3.522M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Vertex Pharmaceuticals, Inc. | 1.100B |
| Basilea Pharmaceutica AG | -- |
| Santhera Pharmaceuticals Holding AG | -- |
| BeOne Medicines Ltd. | 237.40M |
| AC Immune SA | 2.371M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 10.18M |
| Total Expenses (Quarterly) | 101.34M |
| EPS Diluted (Quarterly) | -0.9445 |
| Enterprise Value | 3.777B |
| Gross Profit Margin (Quarterly) | -337.8% |
| Profit Margin (Quarterly) | -895.3% |
| Earnings Yield | -8.59% |
| Normalized Earnings Yield | -8.629 |